UK Cell Reprogramming Market Size & Outlook, 2023-2030
UK cell reprogramming market, 2018-2030 (US$M)
Related Markets
UK cell reprogramming market highlights
- The UK cell reprogramming market generated a revenue of USD 20.1 million in 2023 and is expected to reach USD 41.4 million by 2030.
- The UK market is expected to grow at a CAGR of 10.8% from 2024 to 2030.
- In terms of segment, episomal reprogramming was the largest revenue generating technology in 2023.
- MRNA Reprogramming is the most lucrative technology segment registering the fastest growth during the forecast period.
Cell reprogramming market data book summary
| Market revenue in 2023 | USD 20.1 million |
| Market revenue in 2030 | USD 41.4 million |
| Growth rate | 10.8% (CAGR from 2023 to 2030) |
| Largest segment | Episomal reprogramming |
| Fastest growing segment | MRNA Reprogramming |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming |
| Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies |
Other key industry trends
- In terms of revenue, UK accounted for 5.4% of the global cell reprogramming market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK cell reprogramming market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 41.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Reprogramming Market Scope
Cell Reprogramming Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK cell reprogramming market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell reprogramming market will help companies and investors design strategic landscapes.
Episomal reprogramming was the largest segment with a revenue share of 32.84% in 2023. Horizon Databook has segmented the UK cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2018 to 2030.
The cell reprogramming market in the UK is driven by the presence of numerous cell reprogramming companies, such as Mogrify Limited, bit.bio, and Algocells. These companies are undertaking various business initiatives to gain maximum market share, which is contributing to the growth of the cell reprogramming market in the country.
For instance, in May 2023, Mikonos, Inc., a biotechnology platform specializing in cell therapies through innovative chip technology, announced a new research collaboration with bit.bio. This partnership aims to assess and refine the nonviral delivery of bit.bio's patented safe harbor gene targeting methodology.
The approach involves inducible expressing transcription factor combinations, expediting the advancement of human cells for applications in research, reprogramming human iPSCs, drug discovery, and next-generation cell therapies.
Reasons to subscribe to UK cell reprogramming market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK cell reprogramming market databook
-
Our clientele includes a mix of cell reprogramming market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK cell reprogramming market , including forecasts for subscribers. This country databook contains high-level insights into UK cell reprogramming market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK cell reprogramming market size, by technology, 2018-2030 (US$M)
UK Cell Reprogramming Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
